{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T01:44:10Z","timestamp":1769305450395,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Background\/Objectives<\/jats:title><jats:p>Non-ergot dopamine agonist (NEDA) are recommended as the first-line treatment for patients with early Parkinson's disease (PD) because of their efficacy in treating PD motor symptoms. However, systematic evaluations of the risk of motor complications induced by NEDA and risk factors potentially associated with motor complications are still lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medline, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science were searched for potentially eligible randomized controlled trials. The incidence of motor complications (dyskinesia, motor fluctuations), impulsive-compulsive behaviors and adverse events and clinical disability rating scale (UPDRS) scores were evaluated using standard meta-analytic methods. Metaregression was conducted on the incidence of motor complications (dyskinesia) with treatment duration and NEDA dose as covariates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients treated with NEDA had significantly lower UPDRS total scores, motor scores and activity of daily living (ADL) scores than those receiving a placebo (weighted mean difference (WMD) \u22124.81, 95% CI \u22126.57 to \u22123.05; WMD \u22124.901, 95% CI \u22127.03 to \u22122.77; WMD \u22121.52, 95% CI \u22122.19 to \u22120.84, respectively). Patients in the NEDA and NEDA+open Levodopa (LD) groups had lower odds for dyskinesia than patients in the LD group (OR = 0.21, 95% CI: 0.15\u20130.29; OR = 0.31, 95% CI 0.24\u20130.42, respectively). Metaregressions indicated that the mean LD dose of the NEDA group increased, and the odds of developing dyskinesia increased (<jats:italic>p<\/jats:italic> = 0.012). However, the odds of developing dyskinesia in the NEDA group were not related to treatment duration (<jats:italic>p<\/jats:italic> = 0.308). PD patients treated with NEDA or NEDA+open LD had a lower risk of wearing-off implications than those treated with LD (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05). No significant difference was found between the NEDA and placebo groups in impulsive-compulsive behavior development (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). Patients in the NEDA group were more likely to suffer somnolence, edema, constipation, dizziness, hallucinations, nausea and vomiting than those in the placebo or LD group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>NEDA therapy reduces motor symptoms and improves ADLs in early PD. The odds of developing motor complications were lower with NEDA than with LD, and dyskinesia increased with increasing LD equivalent dose and was not influenced by NEDA treatment duration. Therefore, long-term treatment with an appropriate dosage of NEDA might be more suitable than LD for early PD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Registration<\/jats:title><jats:p>PROSPERO CRD42021287172.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2022.831884","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T02:08:08Z","timestamp":1650679688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Chunxiao","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongji","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingshan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunzhi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.parkreldis.2008.07.004","article-title":"Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis","volume":"15","author":"Baker","year":"2009","journal-title":"Parkinson. Relat. Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40265-019-01098-w","article-title":"Contemporary options for the management of motor complications in Parkinson's Disease: updated clinical review","volume":"79","author":"Cabreira","year":"2019","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s00415-021-10724-1","article-title":"Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis","volume":"269","author":"Cao","year":"2021","journal-title":"J. Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1080\/14656566.2020.1805432","article-title":"An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease","volume":"21","author":"Cerri","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/ene.12318","article-title":"Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta-analysis of levodopa-controlled trials","volume":"21","author":"Chondrogiorgi","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Collaborators","year":"2018","journal-title":"Lancet Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mds.28403","article-title":"Levodopa-induced dyskinesia are mediated by cortical gamma oscillations in experimental parkinsonism","volume":"36","author":"Guttler","year":"2021","journal-title":"Mov. Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0237472","DOI":"10.1371\/journal.pone.0237472","article-title":"Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease","volume":"15","author":"Hong","year":"2020","journal-title":"PLoS ONE"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1756285609339383","article-title":"Improving symptom control in early Parkinson's disease","volume":"2","author":"Isaacson","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.ncl.2013.04.010","article-title":"Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease","volume":"31","author":"Jenner","year":"2013","journal-title":"Neurol. Clin."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-1205-3","article-title":"Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists","author":"Kondo","year":"2002","journal-title":"J. Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"109942","DOI":"10.1016\/j.pnpbp.2020.109942","article-title":"The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease","volume":"102","author":"Napier","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/14740338.2015.988137","article-title":"Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease","volume":"14","author":"Pilleri","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ncl.2019.12.002","article-title":"Pharmacologic treatment of motor symptoms associated with Parkinson Disease","volume":"38","author":"Poewe","year":"2020","journal-title":"Neurol. Clin."},{"key":"B18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/mds.23470","article-title":"The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists","volume":"26","author":"Rasmussen","year":"2011","journal-title":"Mov. Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"j1951","DOI":"10.1136\/bmj.j1951","article-title":"Parkinson's disease: summary of updated NICE guidance","volume":"358","author":"Rogers","year":"2017","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/2046-4053-3-37","article-title":"Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation","volume":"3","author":"Savovic","year":"2014","journal-title":"Syst. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mds.21429","article-title":"Rate of clinical progression in Parkinson's disease. A prospective study","volume":"22","author":"Schrag","year":"2007","journal-title":"Mov. Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1586\/14737175.2015.1001747","article-title":"Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias","volume":"15","author":"Stathis","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"CD006564","DOI":"10.1002\/14651858.CD006564.pub2","article-title":"Dopamine agonist therapy in early Parkinson's disease","volume":"16","author":"Stowe","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s13311-020-00924-4","article-title":"Pharmacological treatment of early motor manifestations of Parkinson Disease (PD)","volume":"17","author":"Sy","year":"2020","journal-title":"Neurotherapeutics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"745947","DOI":"10.1155\/2012\/745947","article-title":"Clinical aspects and management of levodopa-induced dyskinesia","volume":"2012","author":"Tambasco","year":"2012","journal-title":"Parkinsons. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson's disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural. Transm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.parkreldis.2010.10.005","article-title":"The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease","volume":"17","author":"Walker","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease","volume":"28","author":"Warren Olanow","year":"2013","journal-title":"Mov. Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/cns.12239","article-title":"Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhou","year":"","journal-title":"CNS Neurosci. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jocn.2013.10.041","article-title":"Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease","volume":"21","author":"Zhou","year":"","journal-title":"J. Clin. Neurosci."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.831884\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T02:08:12Z","timestamp":1650679692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.831884\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":30,"alternative-id":["10.3389\/fnagi.2022.831884"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2022.831884","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"article-number":"831884"}}